Literature DB >> 9786245

Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging.

D F Brown1, R C Risser, E H Bigio, P Tripp, A Stiegler, E Welch, K P Eagan, C L Hladik, C L White.   

Abstract

Substantial numbers of cortical and subcortical Lewy bodies are seen in approximately one quarter of patients whose brains show sufficient histopathologic changes for a neuropathologic diagnosis of definite Alzheimer disease (AD). This subset of cases has been named the Lewy body variant of AD (LBV). Despite comparable dementia and the presence of neocortical senile plaques in LBV patients, the overall burden of neuropathologic changes, in particular neurofibrillary tangles (NFT), is less than in classic AD. While NFT frequency correlates with dementia severity in classic AD, the cognitive impairment in patients with LBV cannot be completely explained by such changes. Since several studies have suggested a role for synapse loss in relation to dementia severity in classic AD, we decided to investigate the role of synapse loss as a candidate for the cognitive impairment of LBV. The Braak staging method is based upon the distribution and severity of neurofibrillary changes, and one therefore would expect LBV cases to be assigned to lower Braak stages. In the present study we assigned a Braak stage to 14 LBV cases, 31 classic AD cases, and a group of 10 non-demented aged controls. We compared the severity of synapse loss as determined by ELISA immunoassay for synaptophysin and Braak stage among the three diagnostic groups. When compared to normal controls, synaptophysin concentrations were statistically significantly lower in both demented groups. There was comparable synapse loss in LBV and AD despite significantly lower Braak stages in the LBV cases. These results suggest a major role for loss of synapses as the substrate of cognitive impairment in LBV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786245     DOI: 10.1097/00005072-199810000-00007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  18 in total

Review 1.  Synapse loss in dementias.

Authors:  Ryan Clare; Victoria G King; Martin Wirenfeldt; Harry V Vinters
Journal:  J Neurosci Res       Date:  2010-08-01       Impact factor: 4.164

2.  Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors.

Authors:  F Huang; M Buttini; T Wyss-Coray; L McConlogue; T Kodama; R E Pitas; L Mucke
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 3.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

4.  Synaptic protein deficits are associated with dementia irrespective of extreme old age.

Authors:  Michal Schnaider Beeri; Vahram Haroutunian; James Schmeidler; Mary Sano; Peter Fam; Aaron Kavanaugh; Alasdair M Barr; William G Honer; Pavel Katsel
Journal:  Neurobiol Aging       Date:  2011-12-27       Impact factor: 4.673

5.  Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3.

Authors:  Niels R Reinders; Yvonne Pao; Maria C Renner; Carla M da Silva-Matos; Tessa R Lodder; Roberto Malinow; Helmut W Kessels
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-05       Impact factor: 11.205

6.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

Authors:  E Masliah; E Rockenstein; I Veinbergs; Y Sagara; M Mallory; M Hashimoto; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

7.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

8.  Inhibition of amyloid-β plaque formation by α-synuclein.

Authors:  Teresa Bachhuber; Natalie Katzmarski; Joanna F McCarter; Desiree Loreth; Sabina Tahirovic; Frits Kamp; Claudia Abou-Ajram; Brigitte Nuscher; Alberto Serrano-Pozo; Alexandra Müller; Marco Prinz; Harald Steiner; Bradley T Hyman; Christian Haass; Melanie Meyer-Luehmann
Journal:  Nat Med       Date:  2015-06-22       Impact factor: 53.440

9.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

10.  Cerebral amyloid angiopathy in Lewy body disease.

Authors:  K A Jellinger; J Attems
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.